|
ISIN No
|
INE878I01022
|
BSE Code / NSE Code
|
532989 / BAFNAPH
|
Book Value (Rs.)
|
40.64
|
Face Value
|
10.00
|
|
Bookclosure
|
25/09/2024
|
52Week High
|
263
|
EPS
|
4.69
|
P/E
|
56.03
|
|
Market Cap.
|
621.95 Cr.
|
52Week Low
|
78
|
P/BV / Div Yield (%)
|
6.47 / 0.00
|
Market Lot
|
1.00
|
|
Security Type
|
Other
|
|
The company history sections lists out major chronological events that happened to the company.
| Bafna was incorporated on March 28, 1995 with the Registrar of Companies
Tamilnadu and acquired the entire business of Bafna Pharmaceutical, a
proprietary concern of Mr. Bafna Mahaveer Chand.Bafna Pharmaceutical has
been engaged in the business of manufacturing pharmaceutical formulations of
Betalactam and Non Betalactam products. The first manufacturing unit was set
up at Madhavaram during October 1984 for manufacture of tablets with an
installed capacity of 420 lacs tablets p.a. Subsequently the capusule line was
added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line
with an installed capacity of 45000 lts p.a was added in 1990.
Major events in the History of the Company:
Year Event
1981
-Started as a Proprietorship concern
1984
-Set up its first manufacturing unit on 04.10.1984 at Madhavaram with tablet line of installed capacity of 420 Lacs p.a.
1987
-Added Capsules Line with installed capacity of 300 lacs p.a.
1990
-Added Liquid Line with installed capacity of 45,000 ltr. p.a.
-Made its first supplies to Government of Tamilnadu
1994
-Started Contract Manufacturing activity for Crossland Laboratories
-WHO GMP Certification for Madhavarm Unit receives Submitted Dossier for registration for 57 products in Srilanka Made its first export to Srilanka
1995
-Started Supply to ESI corporation.
2003
-Received Export House" Status by Ministry of Commerce & Industry
2005
-Best Supplier" Award by State Pharmaceuticals Corporation of Sri Lanka
-Started Construction of new plant at Grantlyon village Madhavaram Plant approved as per revised Schedule `M'
2006
-Registered 4 products in Ukraine.
-New plant at Grantlyon Inaugurated by Governor of Tamil Nadu, on 02.10.2006.
-Received ISO 9001: 2000 certificate
2007
-Inspection by Ghana Inspectors in 2007 got accreditation.
-Rated as "SE2A" by Dun & Bradstreet
-Manufacturing Licence Received for Grantlyon Unit
-WHO GMP Certification for Grantlyon Unit
2008
-Bafna Pharmaceuticals is entering the capital market with its IPO
-Bafna Pharmaceuticals have received MHRA approval from UK for the Companys new plant at Grantlayon, Chennai.
2009
-ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
-MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
2010
-Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
-Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
2011
-Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
-Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.
-Bafna Pharmaceuticals has signed an agreement with NR Jet, an affiliate of Johnson & Johnson Limited, for acquisition of the TradeMark "RARICAP".
2013
-Bafna Pharmaceutical Launch of RARICAP injection in domestic market
-Bafna Pharmaceuticals receives product approval for Ghana
-Bafna Pharmaceuticals Ltd has recommended a final dividend of Rs. 0.60 per
equity share (6%)
-Bafna Pharmaceutical Launch of new products Afenac, Nocaf, Izabof in domestic market
2014
-Bafna Pharmaceuticals has appointed RS Gowdhaman as Company Secretary & Compliance Officer with effect from October 15, 2014.
2023
-'Bafna Pharmaceuticals Limited awarded with MSME-ZED certified GOLD CERTIFICATE'.
2024
-The Company received All-Round Silver Star - Export Performance Award by Pharmaceuticals Export Promotion Council of India.
|